Aridis Pharmaceuticals (ARDS) stock forecast for 2022
Last update: September 27, 2023 (17:07)Sector: Healthcare
The share price of Aridis Pharmaceuticals, Inc. (ARDS) now
50/200 Day Moving Average: $ / $
This figure corresponds to the Average Price over the previous 50/200 days. For Aridis Pharmaceuticals stocks, the 50-day moving average is the support level today.
For Aridis Pharmaceuticals stocks, the 200-day moving average is the support level today.
Are you interested in Aridis Pharmaceuticals stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Aridis Pharmaceuticals stock price in 2022. How much will one Aridis Pharmaceuticals share be worth in 2022? Is it worth taking profit / loss on Aridis Pharmaceuticals stock now or waiting? What are analysts' forecasts for Aridis Pharmaceuticals stock?
We forecast Aridis Pharmaceuticals stock performance using neural networks based on historical data on Aridis Pharmaceuticals stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account. The Aridis Pharmaceuticals stock prediction results are shown below and presented as a graph, table and text information.
Aridis Pharmaceuticals stock forecasts are adjusted once a day based on the closing price of the previous trading day.
The minimum target price for Aridis Pharmaceuticals analysts is $.
Today 200 Day Moving Average is the support level ( $).
50 Day Moving Average is the support level ( $).
Historical and forecast chart of Aridis Pharmaceuticals stock
The chart below shows the historical price of Aridis Pharmaceuticals stock and a prediction chart for the next year. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Aridis Pharmaceuticals stock price can be found in the table below.
Aridis Pharmaceuticals (ARDS) Forecast for 2022
Aridis Pharmaceuticals information and performance
Aridis Pharmaceuticals, Inc. Is a biopharmaceutical company specializing in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat infections. MABs represent a treatment approach that allows the human immune system to fight infections and is designed to overcome the disadvantages associated with current therapies, such as increased drug resistance, short response times, negative effects on the human microbiome, and lack of differentiation between treatment alternatives. Its product pipeline includes human MABs that target specific pathogens associated with bacterial infections, most notably hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). Its leading candidate product, AR-301, targets the alpha toxin produced by the gram-positive bacteria Staphylococcus aureus, a common pathogen associated with HAP and VAP. Its AR-101 (Aerumab) is a fully human immunoglobulin M targeting P. aeruginosa serotype O11.
Market capitalization of the Aridis Pharmaceuticals, Inc. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of ARDS shares in the company outstanding by the market price of one share.
EBITDA of Aridis Pharmaceuticals is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
Aridis Pharmaceuticals price target for 2022 by month
Related stocks from Healthcare sector
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.